Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

• Váldodahkkit: Hoai‐Thu Thai (Dahkki), Kimiko Koiwai (Dahkki), Yoshihisa Shitara (Dahkki), Hirotaka Kazama (Dahkki), Jean‐Baptiste Fau (Dahkki), Dorothée Semiond (Dahkki), Christine Veyrat‐Follet (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2023-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of serum M‐protein kinetics and its association with p...